Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JCR Pharmaceuticals Co has the GF Score of 47, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes JCR Pharmaceuticals Co
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
JCR Pharmaceuticals Co (FRA:JCR) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
JCR Pharmaceuticals Co GF Score Related Terms
FRA:JCR vs LLY, JNJ, ABBV: GF Score Comparison
For the Drug Manufacturers - General subindustry, JCR Pharmaceuticals Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JCR Pharmaceuticals Co GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JCR Pharmaceuticals Co's GF Score distribution charts can be found below:
* The bar in red indicates where JCR Pharmaceuticals Co's GF Score falls into.
JCR Pharmaceuticals Co (FRA:JCR) has a GF Score of 47 as of Jul. 29, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on JCR Pharmaceuticals Co and its competitors. This is 16% below median its historical median of 56.00. Over the past decade, JCR Pharmaceuticals Co's GF Score has ranged from 42.00 to 76.00.
Is JCR Pharmaceuticals Co's GF Score too high?
JCR Pharmaceuticals Co's current GF Score of 47 is 16% below median its 10-year median of 56.00. Over the past 10 years, this metric has ranged from a low of 42.00 to a high of 76.00. Overall, JCR Pharmaceuticals Co has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JCR Pharmaceuticals Co's GF Score compare to LLY and JNJ?
JCR Pharmaceuticals Co's GF Score of 47 can be compared against companies in the Drug Manufacturers industry. Historically, JCR Pharmaceuticals Co's own GF Score has ranged from 42.00 to 76.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on JCR Pharmaceuticals Co and its competitors. JCR Pharmaceuticals Co's current GF Score is 47, which is 16% below median its own 10-year median of 56.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JCR Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co (FRA:JCR) is currently considered Possible Value Trap. The stock's GF Value™ is €4.19, compared to a current price of €2.72 — trading 35.1% below its estimated fair value. The current GF Score is 47, which is 16% below median its 10-year median of 56.00. JCR Pharmaceuticals Co's overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For JCR Pharmaceuticals Co (FRA:JCR), the current GF Score is 47 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JCR Pharmaceuticals Co (FRA:JCR) Overvalued in 2026?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co stock appears to be undervalued.
The current stock price of €2.72 is trading 35.1% below its estimated GF Value™ of €4.19.
GuruFocus considers JCR Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for FRA:JCR:
GF Score: 47 (16% below median its 10-year median of 56.00)
GF Value™: €4.19 vs. price of €2.72 (35.1% below fair value)
No single metric tells the full story. See the FRA:JCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.
47GF Score
Get the complete analysis for FRA:JCR
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:JCR has been successfully added to your 
